CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02468193
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:43.474339+00:00
Published At: 2020-03-11T00:00:00+00:00
Record Updated At: 2020-05-06
Results Posted At: 2020-03-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cushing\u0027s Syndrome", "Ectopic Corticotropin Syndrome", "Adrenal Adenoma", "Adrenal Carcinoma", "AIMAH", "PPNAD"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-05-06"
protocolSection.identificationModule.nctId: "NCT02468193"
protocolSection.identificationModule.officialTitle: "A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing\u0027s Syndrome Except Cushing\u0027s Disease"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-03-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.